Needham Reiterates Buy on Viridian Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a $30 price target.
June 11, 2024 | 5:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Viridian Therapeutics and maintained a $30 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $30 price target by a reputable analyst suggests a positive outlook for Viridian Therapeutics. This could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100